moving from tirzepatide to retatrutide vs (2026) can you switch from retatrutide

Dual GIP/GLP-1 agonists add GIP receptor activation, which: Amplifies insulin secretion beyond what GLP-1 alone achieves Increases insulin sensitivity in peripheral tissues Appears to shift adipocyte metabolism toward fat oxidation (mechanism still under investigation) May reduce the nausea signal that limits GLP-1 dose escalation (GIP has anti-emetic properties in animal models) The weight loss ceiling for tirzepatide is approximately 20% to 22% of baseline body weight at the 15 mg dose over 72 weeks (SURMOUNT-1 data)

once absorbed and inside the cells it is removed, thus leaving the glutathione molecule intact

In some respects, the mechanism of GLP-1-MK-801 is similar to other therapies targeting GLP-1 receptors, in that it activates neural circuits involved in feeding, appetite, and reward

Contraindications Absolute contraindications include Wilsons Disease or other copper metabolism disorders, known copper allergy or hypersensitivity, and pregnancy or breastfeeding (no safety data exists for systemic use during these periods)